Medications for Opioid Use Disorder: What Providers and Families Should Know

When someone is offered medication for opioid use disorder, families often have questions: What does it do? Is it safe? Does taking medication mean recovery is not real? Providers may be answering those questions while also arranging treatment, follow-up appointments, and support at home.

Medications for opioid use disorder (MOUD) include buprenorphine, methadone, and naltrexone. These FDA-approved treatments work in different ways to reduce opioid use and support recovery. Buprenorphine and methadone reduce withdrawal and cravings, and research links treatment with these medications to lower overdose and death risk. Naltrexone blocks opioid effects and requires a carefully planned start. Choosing a medication is a shared medical decision, not a test of willpower.

This guide explains the differences in plain language, offers practical questions for families, and outlines continuity-of-care considerations for providers. It is education, not a diagnosis or a recommendation to start, stop, or change a particular medication.

What medication treatment is designed to do

Opioid use disorder is a treatable medical condition involving patterns of opioid use that cause significant problems. Cravings, withdrawal, and changes in tolerance can make stopping difficult. Someone may want to stop using opioids and still need medical treatment and ongoing support.

Medication can make withdrawal and cravings more manageable or block opioid effects, depending on the treatment selected. The aim is greater safety and stability so the person can participate in daily life and other care. Improvement can include attending appointments, returning to routines, and addressing health or relationship concerns—not simply reaching a medication-free milestone.

The National Institute on Drug Abuse’s overview of MOUD explains the evidence for these treatments, including reduced overdose risk with buprenorphine and methadone. Benefits are not identical for every medication or every person, and medication does not eliminate all risk.

Detoxification and ongoing treatment are also different. Managing withdrawal may be one part of care, but it does not by itself provide a long-term treatment plan. People should not have to prove that they can manage without medication before discussing evidence-based options.

Understanding the three main medication options

There is no universally best medication. A clinician considers current opioid use, prior treatment, other medicines, medical needs, patient preference, and practical access. The following comparison is a starting point for a conversation, not a way to choose treatment without an assessment.

Buprenorphine: reducing withdrawal and cravings

Buprenorphine partly activates the opioid receptors involved in withdrawal and cravings. Clinicians call it a partial opioid agonist. It can reduce those symptoms without the intense effects associated with uncontrolled opioid use. Available treatments include medicines taken under the tongue and long-acting injections.

Some formulations combine buprenorphine with naloxone to discourage certain forms of misuse. That combination is not a substitute for having overdose-reversal medication available when recommended.

Buprenorphine can be prescribed in office-based care rather than requiring attendance at a specialized methadone program. However, appointment access, pharmacy availability, insurance, and the timing of treatment initiation still matter. Starting it requires medical guidance because, in some circumstances, an incorrectly timed start can trigger sudden withdrawal.

Its pharmacology does not make it risk-free. The prescriber needs to know about alcohol, sedatives, other opioids, and all other medications or supplements. Ask about side effects, safe storage, driving or work concerns, and what to do if a dose or appointment is missed.

Methadone: treatment through an opioid treatment program

Methadone fully activates opioid receptors, but in a medically supervised treatment plan it is used to reduce withdrawal and cravings. It has a substantial evidence base for opioid use disorder. Some people find it helpful when other treatment has not adequately met their needs.

In the United States, methadone for opioid use disorder is generally provided through approved opioid treatment programs. Early treatment may involve frequent visits. Take-home medication arrangements depend on clinical assessment and applicable program rules; daily attendance is not a permanent requirement for everyone.

Monitoring is important because methadone can cause serious adverse effects, including slowed breathing, especially during treatment changes or with interacting substances. Transportation, clinic hours, and work schedules should be discussed as access needs—not treated as evidence that someone lacks commitment to recovery.

Naltrexone: blocking opioid effects

Naltrexone blocks opioid receptors rather than activating them. The extended-release injection used for opioid use disorder is typically given monthly. For some people, this approach fits their preferences and treatment circumstances.

A clinician must confirm that it is safe to start. Beginning naltrexone while opioids remain active in the body can cause severe withdrawal. The necessary opioid-free interval depends on the situation and must be determined medically; this article does not provide a do-it-yourself waiting schedule.

Naltrexone also affects opioid pain treatment. Anyone taking it should tell health professionals before procedures or emergency treatment. Trying to overcome the blockade with more opioids can be dangerous. After treatment is interrupted or stopped, reduced tolerance can increase overdose risk if opioid use resumes. Follow-up and overdose-prevention planning remain important.

Medication-supported recovery is still recovery

The phrase “replacing one addiction with another” can discourage people from considering treatment. It overlooks the difference between compulsive, harmful opioid use and prescribed medication used within a monitored care plan.

Physical dependence means the body has adapted to a substance and withdrawal may occur when it is stopped. That is not, by itself, the same as opioid use disorder. A person taking medication as prescribed may be physically dependent while functioning better and reducing harmful opioid use.

This distinction does not mean misuse or side effects are impossible. It means medication should be evaluated by its clinical role, safety, and the person’s goals—not by a moral judgment. A respectful conversation might begin, “What is this medication helping you manage, and what questions would you like to ask your prescriber?”

Treatment duration varies. Some people receive medication for years. A decision about continuing, changing, or tapering belongs with the person and their qualified clinician. Family pressure to stop, or an arbitrary deadline, is not a substitute for reviewing symptoms, safety, and the support available.

How families can support treatment without taking over

Families do not have to become medication experts to be helpful. They can support access, listen without judgment, and ask what assistance the person actually wants. Adults retain autonomy over their care, and information-sharing requires appropriate permission.

• Ask permission before getting involved. Offer to help prepare questions or attend an appointment if invited.

• Make practical support specific. Transportation, appointment reminders, or help with insurance calls may be useful when welcomed.

• Discuss safety with a professional. Ask about secure storage, overdose-reversal medication, and an emergency response plan.

• Describe observations rather than assigning motives. “You seem unusually sleepy” is more useful than accusing someone of not trying.

• Keep boundaries and support for yourself. Being supportive does not require managing another adult’s medication or ignoring your own needs.

Questions about side effects or treatment changes should go to the prescriber, not be settled through a family vote. If the person agrees, family support and education can create space to discuss communication, expectations, and concerns without making relatives responsible for directing treatment.

Medication, therapy, and the right level of care

Medication and behavioral health care address different needs. Counseling, peer support, and practical assistance can help with relationships, coping skills, housing, routines, and co-occurring symptoms. Access to medication should not be delayed solely because someone cannot yet participate in counseling.

Weekly outpatient appointments may meet one person’s needs. Another may need more frequent clinical contact. An intensive outpatient program offers structured treatment while a person continues living outside the program. It is not a replacement for medically necessary withdrawal management, hospital care, or specialized medication services.

When depression, anxiety, trauma-related symptoms, or other mental health concerns occur alongside opioid use, care for co-occurring conditions can help bring those needs into the same planning conversation. Assessment determines the appropriate setting; opioid use disorder does not automatically mean someone needs IOP.

Waterview Behavioral Health provides adult outpatient behavioral health services in Wallingford, Connecticut. Its published services include therapy, psychiatric care, medication management, family involvement when appropriate, and transition planning. Ask admissions how those services may fit an existing MOUD plan. Do not assume the program dispenses methadone or offers every medication or formulation described here.

Provider considerations: protect continuity across transitions

For therapists, primary care clinicians, and discharge planners, a referral is more useful when medication continuity is addressed alongside behavioral health needs. A person should not arrive at the next setting uncertain about who is prescribing, where medication will be obtained, or whom to contact about a problem.

With appropriate consent and applicable privacy protections, clarify the following before a transition:

• Who is responsible for prescribing or dispensing, and when the next appointment is confirmed.

• Whether pharmacy access, transportation, payment, or clinic scheduling could interrupt care.

• What information the receiving clinician needs about current treatment and medical concerns.

• How questions, side effects, missed appointments, or renewed opioid use will be addressed.

• Which supports remain available outside program hours and after discharge.

These are coordination questions, not instructions for a nonprescribing clinician to change medication. Keep the established prescriber or opioid treatment program involved. Sharing substance use treatment information requires particular attention to consent and applicable confidentiality rules.

Overdose prevention remains part of the plan

MOUD reduces important risks, but it does not make overdose prevention unnecessary. Ask a clinician or pharmacist about naloxone or another appropriate overdose-reversal medication, how to recognize a suspected overdose, and how household members can respond. SAMHSA provides opioid overdose prevention and reversal resources.

If someone may be experiencing an overdose, call 911 immediately and administer available overdose-reversal medication according to its instructions. Follow emergency-dispatch guidance. Do not wait for a routine appointment or an admissions response.

Questions to bring to a treatment conversation

A useful next step is an informed conversation with a qualified medical professional. Ask what options fit the person’s needs, how treatment will start, what monitoring is required, and how ongoing care will remain accessible. Bring concerns about medication, but also bring practical concerns about getting to appointments and filling prescriptions.

For general information about Waterview’s outpatient services and how they may complement an existing care plan, contact the Waterview care team. Families can ask about program information without requesting private treatment details. Providers may use the same route to discuss assessment and coordination within appropriate consent boundaries. An assessment does not guarantee admission or a particular outcome.

Frequently asked questions

Is naloxone the same medication as naltrexone?

No. Naloxone is used to reverse an opioid overdose. Naltrexone is a medication used in ongoing treatment that blocks opioid effects. Similar names do not make them interchangeable; ask a pharmacist or clinician to explain the medicines in the actual care plan.

Can someone receive MOUD while participating in IOP?

Often, yes, when assessment supports outpatient care and medication services can be coordinated. Confirm the program’s actual capabilities, the prescribing arrangement, and appointment access rather than assuming all services occur in one place.

What if someone returns to opioid use during treatment?

A return to use calls for timely medical reassessment and a review of safety, medication access, and support needs. It is not a reason for shame or an automatic conclusion that treatment cannot help. Seek emergency assistance for a suspected overdose.

What if the medication plan is too difficult to access?

Tell the treatment team about barriers such as transportation, pharmacy availability, cost, or appointment timing. Ask what assistance or alternative arrangements are possible. Do not stop or change treatment on your own while trying to solve an access problem.